Ebola, Health Sovereignty and Africa’s Strategic Vulnerability

The resurgence of Ebola in Central and East Africa has revived one of the most important strategic debates on the continent: whether Africa can continue to depend on external donors, foreign supply chains and emergency-led international assistance for its health security.

The 2026 Ebola outbreak in the Democratic Republic of the Congo and Uganda, caused by the Bundibugyo species of Ebola virus, is particularly significant because there is no licensed vaccine or specific approved therapeutic for this strain. The outbreak has therefore exposed a familiar structural weakness: Africa remains highly vulnerable when health emergencies emerge faster than external financing, imported commodities and global response mechanisms can be mobilised.

This study argues that Ebola is not only a public health crisis. It is also a sovereignty issue. Health sovereignty should be understood as the capacity of African states and regional institutions to finance, manufacture, regulate, detect and respond to health threats with reduced dependence on external actors. Such sovereignty does not imply isolation from global cooperation. Rather, it requires a shift from dependency to strategic partnership.

The issue is becoming urgent. Africa CDC has warned that the continent faces an unprecedented financing crisis, while donor support has declined sharply. At the same time, health emergencies have increased, African populations are growing, debt burdens are constraining national budgets, and the continent continues to import more than 90% of its health commodities.

For Africa, health sovereignty is no longer an abstract aspiration. It is becoming a central pillar of national security, economic resilience and geopolitical autonomy.

Ebola as a Strategic Test for African Health Systems

Since its first identification in 1976, Ebola has repeatedly tested the resilience of African health systems. The Democratic Republic of the Congo has experienced more Ebola outbreaks than any other country, reflecting both the ecological conditions in which zoonotic spillovers occur and the difficulty of responding to outbreaks in areas affected by weak infrastructure, conflict, population movement and limited health-system capacity.

The 2014–2016 West African Ebola epidemic, which devastated Guinea, Liberia and Sierra Leone, remains the defining historical warning. It killed more than 11,000 people and demonstrated how quickly a local outbreak can become a regional emergency when surveillance, laboratory capacity, community trust and emergency financing are insufficient.

The 2026 outbreak in the DRC and Uganda has renewed these concerns. According to the World Health Organization, the outbreak was confirmed in May 2026 and involves Bundibugyo virus disease, a species of Ebola for which no licensed vaccine or specific treatment currently exists. WHO also determined that the outbreak constituted a Public Health Emergency of International Concern, requiring international coordination.

This matters because the Ebola response architecture developed after 2014 has not eliminated Africa’s vulnerability. It has improved detection, coordination and response capacity, but many critical tools remain dependent on external financing, foreign manufacturing, international procurement, and emergency donor mobilisation. When those systems are delayed, politicised or underfunded, African states are left exposed.

The Donor Model Is Weakening

The current debate on health sovereignty is being accelerated by the erosion of the traditional donor model. According to reporting by the Associated Press, official development assistance to Africa has fallen from approximately US$26 billion in 2021 to around US$13 billion in 2025. This contraction has coincided with increased geopolitical competition, domestic budget pressures in donor countries, and significant cuts under the Trump administration.

For decades, African governments were able to rely on donor support as a financial cushion during epidemics. That system is now less predictable. As Africa CDC Director-General Dr Jean Kaseya has warned, many African countries still enter outbreaks without budgetary reserves for preparedness or response, forcing them to seek partners after emergencies have already begun.

This creates a dangerous asymmetry. Outbreaks move at biological speed, while donor mobilisation moves at political and bureaucratic speed. In the case of highly infectious diseases such as Ebola, the delay between detection, financing, deployment and community engagement can determine whether an outbreak remains localised or becomes regional.

The lesson is clear: donor assistance can remain useful, but it can no longer serve as the foundation of African health security.

The Historical Roots of Health Sovereignty in Africa

The idea of health sovereignty is not new. It forms part of a broader African political tradition linking development, self-reliance and liberation from external dependency.

In the post-independence period, leaders such as Kwame Nkrumah argued that political independence would remain incomplete without economic and institutional autonomy. Although Nkrumah’s focus was broader than health, his Pan-African vision anticipated today’s debate: fragmented states dependent on external systems would struggle to exercise real sovereignty.

Julius Nyerere’s emphasis on self-reliance in Tanzania also contributed to this tradition. His development philosophy placed social services, rural health, education and community organisation at the centre of nation-building. The premise was that newly independent African states could not outsource the welfare of their populations to external powers.

Thomas Sankara later gave this doctrine one of its most radical expressions in Burkina Faso. His government prioritised vaccination, public health mobilisation, food self-sufficiency and anti-dependency politics. Sankara’s famous critique of external dependence remains influential in contemporary African debates about sovereignty, debt and development.

In the twenty-first century, the language has changed but the strategic problem remains. During the COVID-19 pandemic, African leaders and institutions repeatedly condemned vaccine inequity and the continent’s dependence on imported medical countermeasures. Rwanda’s President Paul Kagame, South Africa’s President Cyril Ramaphosa, former Africa CDC Director John Nkengasong, and several African Union leaders became prominent advocates for local vaccine manufacturing and a stronger continental health architecture.

The current health sovereignty agenda therefore belongs to a longer historical arc. It is the health-sector expression of a much older African demand: the ability to control the strategic systems upon which national survival depends.

From Abuja to Africa CDC: The Long Gap Between Commitments and Capacity

In 2001, African Union member states adopted the Abuja Declaration, committing to allocate at least 15% of national budgets to the health sector. The pledge recognised that the HIV/AIDS, tuberculosis and malaria crises required stronger domestic financing and political prioritisation of health.

More than two decades later, implementation remains uneven. Many countries have failed to meet the Abuja target, and in several cases health expenditure remains vulnerable to fiscal shocks, debt servicing obligations and competing security priorities.

This gap between political commitment and budgetary execution is central to Africa’s vulnerability. Health sovereignty cannot be built through declarations alone. It requires reliable domestic financing, institutional capacity, manufacturing capability, regulatory strength, public trust and trained workforces.

The Africa CDC’s Health Security and Sovereignty Agenda reflects an attempt to close this gap. It frames sovereignty around the ability of African states to finance, produce and govern their own health systems and medical countermeasures. This is a major conceptual shift. It moves the debate away from emergency response and toward structural preparedness.

Africa’s Import Dependence and the Manufacturing Problem

One of Africa’s greatest strategic weaknesses is its dependence on imported medical products. Africa CDC states that more than 90% of health commodities used on the continent are imported. This includes vaccines, medicines, diagnostics and other essential medical supplies.

This dependency became painfully visible during COVID-19, when African countries found themselves at the end of global vaccine supply chains. Wealthier states secured early access to vaccines, while African governments had to rely heavily on COVAX, bilateral donations and delayed procurement mechanisms.

The same vulnerability applies to Ebola. The existence of vaccines and therapeutics for one Ebola species does not automatically solve the problem for another. The 2026 Bundibugyo outbreak demonstrates that Africa needs not only access to existing products but also research capacity, clinical trial infrastructure, genomic surveillance, and flexible manufacturing platforms capable of adapting to emerging pathogens.

The African Union’s Partnerships for African Vaccine Manufacturing, established under Africa CDC in 2021, aims to enable Africa to produce 60% of the vaccines it needs by 2040. This is an ambitious but strategically necessary target. At present, Africa’s production capacity remains far below its needs.

Manufacturing sovereignty will require more than factories. It will require technology transfer, skilled labour, regulatory harmonisation, reliable procurement markets, intellectual property arrangements, regional financing and long-term industrial policy.

Financing Sovereignty: The Hardest Question

The central obstacle to health sovereignty is not vision but financing.

Africa is not poor in resources. The continent holds vast mineral wealth, energy reserves, agricultural potential and a rapidly growing population. Yet public health systems remain chronically underfunded. One reason is that much of the continent’s wealth is lost through illicit financial flows, weak fiscal capture, debt servicing, raw commodity export models and limited local value addition.

The Associated Press report notes that Africa’s debt has risen to approximately US$1.2 trillion and that debt servicing consumes a significant share of public revenue. In many countries, debt repayment now competes directly with health spending. This creates a structural contradiction: governments are being asked to finance health sovereignty at the same time as fiscal space is narrowing.

Co-financing models are emerging as a partial solution. Gavi reported that lower-income countries contributed a record US$302 million toward Gavi-supported vaccines in 2025 and US$1.1 billion over the previous five years. This demonstrates growing domestic ownership of immunisation financing.

However, co-financing must be designed carefully. If donor countries impose unrealistic targets on already strained economies, the result may not be sovereignty but fiscal pressure. Health sovereignty cannot mean simply transferring costs from donors to African governments without addressing debt, tax capacity, procurement inefficiencies and structural economic constraints.

Ebola and the Security Dimension of Health

Ebola also demonstrates that health sovereignty is a security issue.

Outbreaks can destabilise local economies, interrupt trade, close schools, overwhelm hospitals, create fear of public institutions and deepen mistrust between communities and the state. In conflict-affected regions such as eastern DRC, public health response is further complicated by insecurity, population displacement, misinformation and attacks on health workers.

The 2026 outbreak in Ituri illustrates these risks. WHO has emphasised that insecurity, population movement, cross-border trade and humanitarian conditions complicate the response. This means that epidemic control cannot be separated from governance, border management, security sector coordination and community legitimacy.

A sovereign health system must therefore be integrated into national security planning. Surveillance, laboratories, emergency operations centres, trained epidemiologists, local manufacturing and trusted communication systems should be treated as strategic infrastructure.

What Health Sovereignty Would Mean in Practice

For Africa, health sovereignty would have several practical implications.

First, African governments would need to create permanent health emergency funds. Outbreak response should not depend on ad hoc donor appeals after a crisis begins. National and regional contingency financing would allow faster deployment of surveillance teams, protective equipment, laboratories and community engagement.

Second, the continent would need to accelerate pooled procurement. Fragmented national markets make it difficult to negotiate prices or create predictable demand for African manufacturers. Regional procurement systems could lower costs, reduce duplication and support local production.

Third, African states would need to invest in local manufacturing of vaccines, diagnostics, therapeutics and protective equipment. This does not mean every country must manufacture everything. Rather, Africa needs a distributed continental manufacturing ecosystem, with regional specialisation and reliable supply chains.

Fourth, regulatory sovereignty must be strengthened. African-made products require trusted regulatory systems capable of meeting international standards. The African Medicines Agency could play a major role in harmonising approval processes, improving quality assurance and supporting continental markets.

Fifth, health data governance must become a central priority. International partners often request access to surveillance and genomic data, but African countries must ensure that data-sharing arrangements produce reciprocal benefits, including access to diagnostics, vaccines, research partnerships and intellectual property participation.

Finally, community trust must be treated as a sovereign asset. Ebola responses fail when populations distrust authorities, reject health messaging or resist contact tracing. Local legitimacy is as important as laboratory capacity.

Future Implications for Africa

If Africa succeeds in building health sovereignty, the long-term implications would be substantial.

Economically, stronger health systems would reduce the disruptive effects of epidemics on trade, labour markets, tourism, education and investment. Investors increasingly assess health resilience as part of country risk, particularly after COVID-19. Countries able to respond quickly to outbreaks will be more attractive destinations for long-term investment.

Geopolitically, health sovereignty would give Africa greater bargaining power. States that can manufacture vaccines, regulate medicines, generate data and finance emergency responses are less vulnerable to donor conditionality and supply-chain exclusion.

Scientifically, stronger African research ecosystems would ensure that African pathogens are studied in African institutions, with African scientists leading clinical trials, genomic surveillance and therapeutic development. This would reduce the extractive pattern in which biological samples and data leave the continent while benefits return slowly or unevenly.

Politically, health sovereignty would strengthen state legitimacy. Governments that can protect populations during epidemics reinforce public trust. Conversely, governments seen as dependent, absent or reactive during outbreaks risk social instability.

Strategically, the future of African sovereignty will increasingly depend on control over critical systems: food, energy, data, finance, minerals and health. Ebola is a reminder that biological vulnerability can become geopolitical vulnerability.

Risks and Limitations

The health sovereignty agenda also carries risks.

First, there is a danger that the phrase becomes a slogan without implementation. Many African policy concepts have generated strong summit language but weak budgetary follow-through.

Second, local manufacturing may fail if it is not supported by predictable demand. African producers cannot survive on patriotic rhetoric alone. They need procurement commitments, regulatory certainty and competitive financing.

Third, sovereignty should not be confused with isolation. Epidemics are transnational by nature. Africa will still need cooperation with WHO, Gavi, global research institutions and bilateral partners. The goal is not to reject partnerships but to rebalance them.

Fourth, debt and fiscal constraints may prevent many countries from increasing health spending without broader reforms to taxation, illicit financial flows, mineral governance and debt restructuring.

Finally, health sovereignty must be equitable. If only a few stronger African economies build capacity while weaker states remain dependent, continental vulnerability will persist. The agenda must therefore be regional and Pan-African, not merely national.

Ebola has repeatedly exposed the limits of Africa’s health systems. The 2026 outbreak in the DRC and Uganda is especially instructive because it involves a strain without an approved vaccine or specific treatment, in a context of shrinking donor support and rising health emergencies.

The strategic lesson is clear. Africa cannot outsource its health security. External partners will remain important, but dependence on donor financing, imported commodities and emergency assistance leaves the continent vulnerable to delays, conditionality and geopolitical shifts.

Health sovereignty is therefore not a luxury. It is a necessity.

For Africa Strategic Analysis, the central conclusion is that health sovereignty must be understood as a pillar of African statecraft. It is about financing, manufacturing, data, regulation, science, diplomacy and public trust. It is also about the capacity of African states to protect their populations without waiting for external permission or emergency charity.

The future of African health security will depend on whether today’s crises produce another cycle of declarations or a genuine transformation of institutions, budgets and industrial capacity.

If Ebola is the warning, health sovereignty must be the strategy.

Sources: World Health Organization (WHO); Africa Centres for Disease Control and Prevention (Africa CDC); African Union; Gavi, the Vaccine Alliance; International Monetary Fund (IMF); World Bank; United Nations Economic Commission for Africa (UNECA); African Export-Import Bank (Afreximbank); Associated Press; Reuters; The Lancet; BMJ Global Health; Chatham House; Africa Center for Strategic Studies; Abuja Declaration (2001).